The use of PLD with one or more further CoV antiviral agent(s) in the treatment of coronavirus (CoV) infection.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

This invention relates to topical compositions for combating ectoparasites and endoparasites in animals, comprising at least one isoxazoline active agent and a pharmaceutically acceptable carrier, optionally in combination with one or more additional active agents. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

The present invention relates to a pharmaceutical composition for preventing or treating NK/T-cell lymphoma, comprising a phosphodiesterase type 5 inhibitor, the pharmaceutical composition being for inhibiting the reactivation of the Epstein-Barr virus (EBV) induced by a HDAC inhibitor; an anticancer therapy adjuvant composition; and a health functional food. By using the pharmaceutical composition for preventing, alleviating or treating NK/T-cell lymphoma, according to the present invention, EBV reactivation, induced by a HDAC inhibitor used as an anticancer agent for NK/T-cell lymphoma, may be inhibited, and thus side-effects of the HDAC inhibitor may be reduced, and an anticancer effect may be notably increased. Thus, the present invention may be widely used in the pharmaceutical industry on the basis of said effects.

The present invention relates to a pharmaceutical composition for preventing or treating NK/T-cell lymphoma, comprising a phosphodiesterase type 5 inhibitor, the pharmaceutical composition being for inhibiting the reactivation of the Epstein-Barr virus (EBV) induced by a HDAC inhibitor; an anticancer therapy adjuvant composition; and a health functional food. By using the pharmaceutical composition for preventing, alleviating or treating NK/T-cell lymphoma, according to the present invention, EBV reactivation, induced by a HDAC inhibitor used as an anticancer agent for NK/T-cell lymphoma, may be inhibited, and thus side-effects of the HDAC inhibitor may be reduced, and an anticancer effect may be notably increased. Thus, the present invention may be widely used in the pharmaceutical industry on the basis of said effects.

The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.

The present disclosure relates to methods of a malignant rhabdoid tumor (MRT), a rhabdoid tumor of the kidney (RTK), an atypical teratoid/rhabdoid tumor (AT/RT), an epithelioid malignant peripheral nerve sheath tumor, a myoepithelial carcinoma, and/or a renal medullary carcinoma by using an EZH2 inhibitor in combination with one or more additional treatment modalities.